Pain Management Devices Market to Reach $45,240.0 Million by 2035.
Pain management devices market is driven by the increasing prevalence of chronic pain disorders, rising geriatric population, and the growing demand for minimally invasive pain management therapies worldwide. The market is witnessing significant adoption of neurostimulator devices, analgesic infusion pumps, and ablation devices for the treatment of cancer pain, neuropathic pain, musculoskeletal pain, facial pain, migraine pain, and other chronic pain conditions. In addition, technological advancements in neuromodulation systems, increasing awareness regarding non-opioid pain management solutions, and expanding healthcare infrastructure are further accelerating market growth globally.
Browse the full report description of “Pain Management Devices Market Size, Share & Trends Analysis by Application (Cancer Pain, Neuropathic Pain, Musculoskeletal Pain, Facial and Migraine Pain, Others), by Device Type (Neurostimulator Devices, Analgesic Infusion Pumps, Ablation Devices), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/pain-management-devices-market
Interleukin-targeted biologic therapies for respiratory diseases segment is expected to account for a major market share in 2026
Interleukin-targeted biologic therapies for respiratory diseases are expected to hold a major market share in 2026, primarily due to the increasing prevalence of chronic respiratory disorders and growing adoption of precision biologic treatments for inflammatory lung diseases. These therapies specifically target immune pathways associated with type-2 inflammation and severe respiratory complications, improving disease management and reducing exacerbation risks in COPD patients. The FDA approval received by Dupixent from Sanofi and Regeneron Pharmaceuticals for COPD with type-2 inflammation highlights the expanding role of interleukin-targeted biologics in respiratory medicine. Increasing demand for advanced targeted therapies and rising awareness regarding personalized treatment approaches are expected to significantly support segment growth.
IL-23 inhibitor therapies segment is expected to account for a major market share in 2026
IL-23 inhibitor therapies are expected to hold a major market share in 2026 owing to the increasing utilization of targeted biologic therapies for autoimmune and inflammatory bowel diseases across North America. These therapies selectively inhibit interleukin-23 pathways involved in chronic inflammation and immune-mediated gastrointestinal disorders, supporting improved clinical outcomes and long-term disease management. The FDA approval announced by Johnson & Johnson for TREMFYA in ulcerative colitis reflects the growing expansion of IL-23 inhibitor therapies within gastroenterology treatment markets. Increasing diagnosis rates of inflammatory bowel diseases and continued advancement of immunology-based therapeutics are expected to further accelerate segment growth.
Interleukin inhibitor therapies for inflammatory bowel disease segment is expected to account for a major market share in 2026
Interleukin inhibitor therapies for inflammatory bowel disease are expected to hold a major market share in 2026 due to the rising prevalence of ulcerative colitis and increasing adoption of advanced biologic therapies targeting inflammatory immune pathways. These therapies are increasingly preferred for managing moderate-to-severe inflammatory bowel disease owing to their effectiveness in reducing inflammation, improving remission rates, and supporting long-term patient outcomes. The FDA approval received by SKYRIZI from AbbVie for moderately to severely active ulcerative colitis highlights the expanding adoption of IL-23 inhibitor therapies within inflammatory bowel disease treatment. Growing investments in immunology research and increasing availability of targeted biologic therapies are expected to significantly contribute to the growth of the interleukin inhibitor therapies segment.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404